Web appendix 3

Study names

Trial	Full name	Additional identifier
ADAPT	Alzheimer's Disease Anti-Inflammatory Prevention Trial	NCT00007189
Aisen 2003	N/a	NCT00004845
Geusens 2004	Protocol 111	N/a
APC	Adenoma Prevention with Celecoxib	NCT00005094
GAIT	Glucosamine/Chondroitin Arthritis Intervention Trial	NCT00032890
IQ5-97-02-001	N/a	N/a
PreSAP	Prevention of Colorectal Sporadic Adenomatous Polyps	NCT00141193
Lehmann 2005	Protocol 2361	NCT00367315
APPROVe	Adenomatous Polyp Prevention on Vioxx	N/a
Reines 2004	Protocol 091	N/a
Thal 2005	Protocol 078	N/a
VICTOR	Vioxx in Colorectal Cancer Therapy: Definition of Optimal Regime	NCT00031863
ViP	VIOXX in Prostate Cancer Prevention	NCT00060476
A3191152	N/a	NCT00643799
SUCCESS-1 (USA/Canada)	Successive Celecoxib Efficacy and Safety Studies in Osteoarthritis (centres in USA and Canada)	Protocol I49-98-02-096
ADVANTAGE	Assessment of Differences between Vioxx and Naproxen To Ascertain Gastrointestinal Tolerability and Effectiveness	Protocol 102
VIGOR	Vioxx GI Outcomes Research	Protocol 088
TARGET (0117)	Therapeutic Arthritis Research and Gastrointestinal Event Trial	Protocl 117
CLASS (N49-98-02-035)	Celecoxib Long-term Arthritis Safety Study	Protocol N49-98-02-035
TARGET (2332)	Therapeutic Arthritis Research and Gastrointestinal Event Trial	Protocol 2332
CAESAR	Celecoxib Study of Osteoarthritis in Elderly Patients: Long Term Safety and Pharmacoeconomic Aspects	N/a
CLASS (N49-98-02-102)	Celecoxib Long-term Arthritis Safety Study	Protocol N49-98-02-102

Emery 1999	N/a	Protocol N49-98-02-041
SUCCESS-1 (World)	Successive Celecoxib Efficacy and Safety Studies in Osteoarthritis (centres worldwide but not in USA or Canada)	Protocol I49-98-02-096
EDGE	Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness	NCT00092703
EDGE II	Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness	NCT00092742
MEDAL	Multinational Etoricoxib and. Diclofenac Arthritis Long Term	NCT00250445
Cannon 2000	Protocol 035	N/a
Saag 2000	Protocol 034	N/a
Fleischmann 2003	Protocol 109	N/a
Tannenbaum 2004	Protocol 112	N/a

References

w1 Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT). PLoS Clin Trials 2006;1:e33.

w2 National Institute on Aging. ADAPT: Alzheimer's Disease Anti-inflammatory Prevention Trial. Available at: http://www.jhucct.com/adapt/default.htm. Accessed Apr 20, 2009.

w3 Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289:2819-26.

w4 Aisen P. Personal communication: E-mail, Re: Alzheimer's Disease Cooperative Study - JAMA 2003; 289:2819. Dec 11, 2006.

w5 Geusens P, Alten R, Rovensky J, Sloan VS, Krammer G, Kralidis G, et al. Efficacy, safety and tolerability of lumiracoxib in patients with rheumatoid arthritis. Int J Clin Pract 2004;58:1033-41.

w6 Rebuli R. Personal communication: E-mail, Re: Fw: Safety of NSAIDs- additional data. May 10, 2007.

w7 Rebuli R. Personal communication: E-mail, Safety of NSAIDs- additional data from Novartis. Feb 19, 2008.

w8 Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005;352:1071-80.

w9 Pfizer Pharmaceuticals Inc. APC. Available at: http://www.clinicalstudyresults.org/drugdetails/?study_name=apc&sort=c.company_name&page=1&drug_id=2146. Accessed Feb 12, 2007.

w10 Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006;354:795-808.

w11 Pfizer Pharmaceuticals Inc. Advisory Committee Briefing Document: celecoxib and valdecoxib cardiovascular safety. Arthritis Advisory Committee, Drug Safety and Risk Management Advisory Committee, 16-18 February 2005. 2005.

w12 Pfizer Pharmaceuticals Inc. IQ5-97-02-001. Available at: http://www.clinicalstudyresults.org/drugdetails/?study_name=IQ5-97-02-001&sort=c.company_name&page=1&drug_id=76. Accessed Feb 20, 2007.

w13 Pan SX. Personal communication: E-mail, Re: Trelle/Juni meta-analysis. Jun 27, 2007.

w14 Cawkwell G. Personal communication: E-mail, Re: NSAID safety. Feb 26, 2008.

w15 Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.

w16 Lehmann R, Brzosko M, Kopsa P, Nischik R, Kreisse A, Thurston H, et al. Efficacy and tolerability of lumiracoxib 100 mg once daily in knee osteoarthritis: a 13-week, randomized, double-blind study vs. placebo and celecoxib. Curr Med Res Opin 2005;21:517-26.

w17 Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005;352:1092-102.

w18 Merck & Inc. Rofecoxib: FDA Advisory Committee Background Information (January 21, 2005). 2005.

w19 Thal LJ, Ferris SH, Kirby L, Block GA, Lines CR, Yuen E, et al. A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-15.

w20 Kerr DJ, Dunn JA, Langman MJ, Smith JL, Midgley RS, Stanley A, et al. Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. N Engl J Med 2007;357:360-9.

w21 Cancer Research Campaign Clinical Trials Centre. Rofecoxib after surgery in treating patients with stage II or stage III colorectal cancer. Available at: http://clinicaltrials.gov/ct2/show/NCT00031863?term=nct00031863&rank=1. Accessed Aug 23, 2006.

w22 Oncology Clinical Trials Office. VICTOR. Available at: http://www.octo-oxford.org.uk/Trials/Victor/. Accessed Aug 23, 2006.

w23 Merck & Inc. ViP. Available at: http://www.clinicalstudyresults.org/drugdetails/?inn_name_id=44&indication_keyword=prostate&sort=c.company_name&page=1&drug_id=783. Accessed Dec 20, 2006.

w24 Pfizer Pharmaceuticals Inc. A3191152. Available at: http://www.clinicalstudyresults.org/drugdetails/?inn_name_id=55&study_name=A3191152&sort=c.company_name&page=1&drug_id=1814. Accessed Apr 5, 2006.

w25 Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 2006;119:255-66.

w26 Pfizer Pharmaceuticals Inc. SUCCESS-1. Available at: http://www.clinicalstudyresults.org/drugdetails/?study_name=success-1&sort=c.company_name&page=1&drug_id=1846. Accessed Feb 20, 2007.

w27 Villalba ML. FDA: Medical Officer Review, complete response to approvable letter for 21-042/S 007 and 21-052/S 004. 2001.

w28 Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, et al. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Intern Med 2003;139:539-46.

w29 Annals of Internal Medicine. Correction: Report of specific cardiovascular outcomes of the ADVANTAGE trial. Ann Intern Med 2006;144:943.

w30 Li Q. FDA Statistical Review: NDA21-042s-007, gastrointestinal (GI) safety label change. 2001.

w31 Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8, 2 p following 1528.

w32 Novartis Pharmaceuticals Corp. Lumiracoxib (COX189): Background document for Novartis presentation to FDA Advisory Committee (February 16-18, 2005). 2005.

w33 Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004;364:675-84.

w34 Goldkind L, Witter J. FDA Medical Officer Review: Celebrex Capsules, NDA 20-998/S-009. 2000.

w35 Lu HL. FDA Statistical Review and Evaluation NDA20-998. 2001.

w36 Pfizer Pharmaceuticals Inc. CAESAR. Available at: http://www.clinicalstudyresults.org/documents/company_study_1844_0.pdf. Accessed Dec 20, 2006.

w37 Tolerability and pharmacoeconomic assessment of celecoxib 200 mg once daily and diclofenac 50 mg twice daily in elderly patients with osteoarthritis of the hip or knee. The European League Against Rheumatism Annual Congress; 2004 Jun 11; Berlin, Germany.

w38 Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.

w39 Rappaport BA. FDA Background Package for the Arthritis Advisory Committee Meeting, April 12, 2007. 2007.

w40 Baraf HS, Fuentealba C, Greenwald M, Brzezicki J, O'Brien K, Soffer B, et al. Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. J Rheumatol 2007;34:408-20.

w41 Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, et al. Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs

diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II). Ann Rheum Dis 2008;67:315-22.

w42 Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 2006;368:1771-81.

w43 Villalba ML. FDA: Medical Officer Review, Vioxx, NDA 21-042 (capsules) and NDA 21-052 (oral solution). 1998.

w44 Pelayo JC. FDA: Memorandum; Consultation NDA 21-042, review of cardivascular and renal safety database. 1998.

w45 Cannon GW, Caldwell JR, Holt P, McLean B, Seidenberg B, Bolognese J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Rofecoxib Phase III Protocol 035 Study Group. Arthritis Rheum 2000;43:978-87.

w46 Saag K, van der Heijde D, Fisher C, Samara A, DeTora L, Bolognese J, et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal anti-inflammatory drugs: a 6-week and a 1-year trial in patients with osteoarthritis. Osteoarthritis Studies Group. Arch Fam Med 2000;9:1124-34.

w47 Fleischmann R, Sheldon E, Maldonado-Cocco J, Dutta D, Yu S, Sloan VS. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clin Rheumatol 2006;25:42-53.

w48 Tannenbaum H, Berenbaum F, Reginster JY, Zacher J, Robinson J, Poor G, et al. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib. Ann Rheum Dis 2004;63:1419-26.